LUPKYNIS® Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

Jan 17, 2024

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year

Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS

News Provided by Business Wire via QuoteMedia